BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

795 related articles for article (PubMed ID: 11712796)

  • 21. Dose escalation of amifostine for radioprotection during pelvic accelerated radiotherapy.
    Koukourakis MI; Kyrgias G; Panteliadou M; Papadopoulou A; Tsiarkatsi M; Papachristou E; Bebeli M
    Am J Clin Oncol; 2013 Aug; 36(4):338-43. PubMed ID: 22643562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer.
    Machtay M; Rosenthal DI; Chalian AA; Lustig R; Hershock D; Miller L; Weinstein GS; Weber RS
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):72-7. PubMed ID: 15093901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiochemotherapy with cetuximab, cisplatin, and amifostine for locally advanced head and neck cancer: a feasibility study.
    Koukourakis MI; Tsoutsou PG; Karpouzis A; Tsiarkatsi M; Karapantzos I; Daniilidis V; Kouskoukis C
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):9-15. PubMed ID: 19744802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hypofractionated accelerated radiotherapy, cytoprotection and capecitabine in the treatment of rectal cancer: a feasibility study.
    Koukourakis MI; Simopoulos C; Pitiakoudis M; Lyratzopoulos N; Romanidis K; Giatromanolaki A; Polychronidis A; Kouklakis G; Sivridis E; Minopoulos G; Manolas K
    Anticancer Res; 2008; 28(5B):3035-40. PubMed ID: 19031952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity.
    Kouloulias VE; Kouvaris JR; Pissakas G; Kokakis JD; Antypas C; Mallas E; Matsopoulos G; Michopoulos S; Vosdoganis SP; Kostakopoulos A; Vlahos LJ
    Strahlenther Onkol; 2004 Sep; 180(9):557-62. PubMed ID: 15378186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amifostine--a radioprotector in locally advanced head and neck tumors.
    Schönekäs KG; Wagner W; Prott FJ
    Strahlenther Onkol; 1999 Nov; 175 Suppl 4():27-9. PubMed ID: 10584137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
    Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the protective effect of amifostine on radiation-induced pulmonary toxicity.
    Vujaskovic Z; Feng QF; Rabbani ZN; Samulski TV; Anscher MS; Brizel DM
    Exp Lung Res; 2002; 28(7):577-90. PubMed ID: 12396250
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Escalated hyperfractionated accelerated radiation therapy for locally advanced non-small cell lung cancer: a clinical phase II trial.
    Chen GY; Jiang GL; Qian H; Wang LJ; Yang HJ; Fu XL; Wu KL; Zang Z; Zhao S
    Radiother Oncol; 2004 May; 71(2):157-62. PubMed ID: 15110448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
    Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
    J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Residual chromosomal damage after radiochemotherapy with and without amifostine detected by 24-color FISH.
    Kuechler A; Dreidax M; Pigorsch SU; Liehr T; Claussen U; Wendt TG; Dunst J
    Strahlenther Onkol; 2003 Jul; 179(7):493-8. PubMed ID: 12835887
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
    Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
    McCumber LM
    Med Dosim; 2004; 29(2):139-43. PubMed ID: 15191764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachytherapy.
    Wazer DE; Kaufman S; Cuttino L; DiPetrillo T; Arthur DW
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):489-95. PubMed ID: 16246495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypofractionation in radiotherapy. An investigation of injured Swedish women, treated for cancer of the breast.
    Friberg S; Rudén BI
    Acta Oncol; 2009; 48(6):822-31. PubMed ID: 19504371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
    Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
    J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 40.